Asco 2023 – Trop2 could validate Merck’s savvy deal with Kelun
In Trop2 Merck & Co might have got itself an ADC at least as good as Gilead and Astra/Daiichi’s leaders, for a fraction of the price.
Asco 2023 preview – Tigit lives again
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Here come the PD-1 agonists
Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?
A blockbuster year could be building
If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
Iteos – and GSK – keep the faith
With Tigit out of favour Belgium’s Iteos reckons it could have the best possible PD-(L)1 combo, but does GSK share its optimism?